Elnara Fazio-Eynullayeva

Elnara Fazio-Eynullayeva

Auto-generated profile, based on publicly available information

Elnara Fazio-Eynullayeva

Novo Nordisk lnc

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SHStephanie L. Harrison
Stephanie L. Harrison
EFElnara Fazio-Eynullayeva
Elnara Fazio-Eynullayeva
DLDeirdre Lane
Deirdre Lane
PUPaula Underhill
Paula Underhill
Gregory LipGregory Lip
Gregory Lip
At the beginning of June 2020, there were nearly 7 million reported cases of coronavirus disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19. The objective of this study was to determine associations between comorbidities listed in the Charlson comorbidity index and mortality among patients in the United States with COVID-19. A retrospective cohort study of adults with COVID-19 from 24 healthcare organizations in the US was conducted. The study included adults aged 18–90 years with COVID-19 coded in their electronic medical records between January 20, 2020, and May 26, 2020. Results were also stratified by age groups (<50 years, 50–69 years, or 70–90 years). A total of 31,461 patients were included. Median age was 50 years (interquartile range [IQR], 35–63) and 54.5% (n = 17,155) were female. The most common comorbidities listed in the Charlson comorbidity index were chronic pulmonary disease (17.5%, n = 5,513) and diabetes mellitus (15.0%, n = 4,710). Multivariate logistic regression analyses showed older age (odds ratio [OR] per year 1.06; 95% confidence interval [CI] 1.06–1.07; p < 0.001), male sex (OR 1.75; 95% CI 1.55–1.98; p < 0.001), being black or African American compared to white (OR 1.50; 95% CI 1.31–1.71; p < 0.001), myocardial infarction (OR 1.97; 95% CI 1.64–2.35; p < 0.001), congestive heart failure (OR 1.42; 95% CI 1.21–1.67; p < 0.001), dementia (OR 1.29; 95% CI 1.07–1.56; p = 0.008), chronic pulmonary disease (OR 1.24; 95% CI 1.08–1.43; p = 0.003), mild liver disease (OR 1.26; 95% CI 1.00–1.59; p = 0.046), moderate/severe liver disease (OR 2.62; 95% CI 1.53–4.47; p < 0.001), renal disease (OR 2.13; 95% CI 1.84–2.46; p < 0.001), and metastatic solid tumor (OR 1.70; 95% CI 1.19–2.43; p = 0.004) were associated with higher odds of mortality with COVID-19. Older age, male sex, and being black or African American (compared to being white) remained significantly associated with higher odds of death in age-stratified analyses. There were differences in which comorbidities were significantly associated with mortality between age groups. Limitations include that the data were collected from the healthcare organization electronic medical record databases and some comorbidities may be underreported and ethnicity was unknown for 24% of participants. Deaths during an inpatient or outpatient visit at the participating healthcare organizations were recorded; however, deaths occurring outside of the hospital setting are not well captured. Identifying patient characteristics and conditions associated with mortality with COVID-19 is important for hypothesis generating for clinical trials and to develop targeted intervention strategies.

1 October 2019 in Radiology
Verified
Journal Article
Closed access
SBSteven T. Bird
Steven T. Bird
KGKate Gelperin
Kate Gelperin
LSLeyla Sahin
Leyla Sahin
KBKaren B. Bleich
Karen B. Bleich
EFElnara Fazio-Eynullayeva
Elnara Fazio-Eynullayeva
IKIra Krefting
Ira Krefting
This study identified higher rates of exposure to gadolinium-based contrast agents (GBCAs) during the first few weeks of pregnancy when compared with rates of exposure later in pregnancy, suggestin... BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during pregnancy has not been established, and the use of GBCAs during pregnancy is not recommended unless it is essential to...

11 November 2021 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
BBBen Buckley
Ben Buckley
IKIris A de Koning
Iris A de Koning
SHStephanie L. Harrison
Stephanie L. Harrison
EFElnara Fazio-Eynullayeva
Elnara Fazio-Eynullayeva
PUPaula Underhill
Paula Underhill
DTDick H J Thijssen
Dick H J Thijssen
Aims: Accumulating evidence questions the clinical value of percutaneous coronary intervention (PCI) for patients with chronic coronary syndrome (CCS). We therefore compare the impact of exercise-based cardiac rehabilitation (CR) vs. PCI in patients with CCS on 18-month mortality and morbidity, and evaluate the effects of combining PCI with exercise-based CR. Methods and results: A retrospective cohort study was conducted in March 2021. An online, real-world dataset of CCS patients was acquired, utilizing TriNetX, a global federated health research network. Patients with CCS who received PCI were first compared with patients who were prescribed exercise-based CR. Second, we compared patients who received both CR + PCI vs. CR alone. For both comparisons, patients were propensity-score matched by age, sex, race, comorbidities, medications, and procedures. We ascertained 18-month incidence of all-cause mortality, rehospitalization, and cardiovascular comorbidity [stroke, acute myocardial infarction (AMI), and new-onset heart failure]. The initial cohort consisted of 18 383 CCS patients. Following propensity score matching, exercise-based CR was associated with significantly lower odds of all-cause mortality [0.37 (95% confidence interval (CI): 0.29–0.47)], rehospitalization [0.29 (95% CI: 0.27–0.32)], and cardiovascular morbidities, compared to PCI. Subsequently, patients that received both CR + PCI did not have significantly different odds for all-cause mortality [1.00 (95% CI: 0.63–1.60)], rehospitalization [1.00 (95% CI: 0.82–1.23)], AMI [1.11 (95% CI: 0.68–1.81)], and stroke [0.71 (95% CI: 0.39–1.31)], compared to CR only. Conclusions: Compared to PCI, exercise-based CR associated with significantly lower odds of 18-month all-cause mortality, rehospitalization, and cardiovascular morbidity in patients with CCS, whilst combining PCI and exercise-based CR associated with lower incident heart failure only.

8 March 2022 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
JLJack W. London
Jack W. London
EFElnara Fazio-Eynullayeva
Elnara Fazio-Eynullayeva
MPMatvey B. Palchuk
Matvey B. Palchuk
CMChristopher McNair
Christopher McNair
PURPOSE: This is an update to a previously published report characterizing the impact that efforts to control the COVID-19 pandemic have had on the normal course of cancer-related encounters. METHODS: Data were analyzed from 22 US health care organizations (members of the TriNetX global network) having relevant, up-to-date encounter data. Although the original study compared encounter data pre–COVID-19 (January-April 2019) with the corresponding months in 2020, this update considers data through April 2021. As before, cohorts were generated for all neoplasm patients (malignant, benign, in situ, and of unspecified behavior), all new incidence neoplasm patients, exclusively malignant neoplasm patients, and new incidence malignant neoplasm patients. Data on the initial cancer stage were available for calendar year 2020 from about one third of the study's organizations. RESULTS: Although COVID-19 cases fluctuated through 2021, newly diagnosed cancers closely paralleled the prepandemic base year 2019. Similarly, screening for breast, colorectal, and cervical cancers quickly recovered beginning in May 2020 to prepandemic numbers. Preliminary data for the initial cancer stage showed no significant difference ( P > .10) in distribution for breast or colon cancers between 2019 and 2020. CONCLUSION: Although the number of COVID-19 cases fluctuated, the steep declines observed during March and April 2020 in screening for breast and colon cancer and patients with newly diagnosed cancer did not continue through the rest of 2020 and into April 2021. Screening and new incidence cancer numbers quickly rose compared with prepandemic levels. The concern that more patients with advanced-stage cancer would be seen in the months following the drastic dips of March-April 2020 was not realized as the major disruption to normal cancer care was limited to these 2 months.

5 February 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LTLockwood G. Taylor
Lockwood G. Taylor
SBSteven T. Bird
Steven T. Bird
DSDanijela Stojanovic
Danijela Stojanovic
STSengwee Toh
Sengwee Toh
JMJudith C. Maro
Judith C. Maro
JLJennifer G. Lyons
Jennifer G. Lyons

11 December 2019 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SDSarah K. Dutcher
Sarah K. Dutcher
EFElnara Fazio‐Eynullayeva
Elnara Fazio‐Eynullayeva
EEEfe Eworuke
Efe Eworuke
ACAmanda Carruth
Amanda Carruth
EDElizabeth C. Dee
Elizabeth C. Dee
JLJennifer G. Lyons
Jennifer G. Lyons